Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

Investing.com -- Allurion Technologies (NYSE: ALUR)股价飙升350%，此前该公司宣布计划启动一项临床研究，旨在优化GLP-1疗法与Allurion计划结合使用时的肌肉质量。